中华皮肤科杂志 ›› 2011, Vol. 44 ›› Issue (6): 393-395.

• 论著 • 上一篇    下一篇

皮肤划痕症患者治疗前后血中组胺含量及氧化活性能力测定

杨义成1,吴海斌2,肖海珍3,石家宴3,石建萍4,孙辉5,陈华5   

  1. 1. 深圳市宝安区沙井人民医院皮肤性病科
    2. 深圳市宝安区沙井人民医院
    3. 深圳市沙井人民医院皮肤科
    4. 深圳市沙井人民医院
    5. 深圳市沙井医院皮肤科
  • 收稿日期:2010-08-13 修回日期:2010-09-10 出版日期:2011-06-15 发布日期:2011-06-02
  • 通讯作者: 杨义成 E-mail:shijie752001@yahoo.com.cn

Measurement of plasma histamine level and oxidative status in patients with dermatographism before and after treatment

  • Received:2010-08-13 Revised:2010-09-10 Online:2011-06-15 Published:2011-06-02

PDF

30

赞

摘要：

目的 探讨皮肤划痕症患者经抗组胺药物治疗后组胺及氧化活性水平。方法 85例皮肤划痕症患者给予地氯雷他定或西替利嗪治疗4周，在治疗前后用ELISA检测血中组胺含量以及血清超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-PX）、丙二醛（MDA）含量，并与正常对照组相比，同时观察药物疗效。结果 地氯雷他定和西替利嗪治疗皮肤划痕症的有效率分别为83.72%和78.57%，两组疗效差异无统计学意义（χ2 = 0.369，P > 0.05）。皮肤划痕症患者治疗前血中组胺（3.87 ± 1.21）高于正常人对照组（1.76 ± 0.56，P < 0.05）；SOD（86.29 ± 19.9），GSH-PX（74.52 ± 47.67）活性低于对照组（SOD 112.12 ± 27.88，GSH-PX 915.06 ± 115.96，P < 0.05），MDA（3.86 ± 1.03）高于对照组（2.19 ± 0.82，P < 0.05）。患者组治疗后组胺水平降低（1.61 ± 0.47，P < 0.05），SOD变化差异无统计学意义，GSH-PX（921.46 ± 157.37）活性增高（P < 0.05），MDA（2.65 ± 0.77）含量下降（P < 0.05）。结论 皮肤划痕症患者血中组胺含量增高，存在氧化-抗氧化失衡。地氯雷他定与西替利嗪治疗有效。

关键词: 组胺

Abstract:

Objective To determine the levels of plasma histamine and oxidative status in patients with dermatographism before and after the treatment with anti-histamine drugs. Methods Totally, 85 patients with dermatographism were randomly divided into two groups to receive oral desloratadine and cetirizine respectively for 4 weeks. Enzyme linked immunosorbent assay （ELISA） was performed to detect the plasma level of histamine, superoxide dismutases （SOD）, glutathion peroxidase （GSH-PX） and malondialdehyde （MDA） in all the patients before and after the treatment and in 15 normal human controls. The efficacy of desloratadine and cetirizine for dermatographism was estimated. Results The response rate was 83.72% and 78.57% in patients treated with desloratadine and those with cetirizine, respectively （χ2 = 0.369, P > 0.05）. The untreated patients with dermatographism showed an elevation in the plasma level of histamine （3.87 ± 1.21 ng/ml vs. 1.76 ± 0.56 ng/ml, P < 0.05） and MDA （3.86 ± 1.03 nmol/ml vs. 2.19 ± 0.82 nmol/ml, P < 0.05）, but a decline in the activity of SOD （86.29 ± 19.9 U/ml vs. 112.12 ± 27.88 U/ml, P < 0.05） and GSH-PX （74.52 ± 47.67 vs. 915.06 ± 115.96, P < 0.05） compared with the normal human controls. The treatment with antihistamine induced a reduction in the plasma level of histamine （1.61 ± 0.47 ng/ml vs. 3.87 ± 1.21 ng/ml, P < 0.05） and MDA （2.65 ± 0.77 nmol/ml vs. 3.86 ± 1.03 nmol/ml, P < 0.05）, but an increment in the activity of GSH-PX （921.46 ± 157.37 vs. 74.52 ± 47.67, P < 0.05） with no changes of SOD in patients with dermatographism. Conclusions In patients with dermatographism, plasma histamine is increased and there is an imbalance of oxidation-antioxidation. Desloratadine and cetirizine are effective for the treatment of dermatographism.

Key words: Histame